[144] Blend Labs, Inc. SEC Filing

Rhea-AI Filing Summary

Blend Labs (BLND) received a Form 144 notice indicating an intended sale of 25,000 shares of common stock through Charles Schwab & Co., Inc. with an aggregate market value of $83,509, targeting an approximate sale date of October 15, 2025 on the NYSE. The form lists 255,696,747 shares outstanding.

The seller acquired these 25,000 shares on February 17, 2020 via “Exercise and Hold,” paid in cash. Recent activity disclosed three prior sales of 25,000 shares each on July 15, 2025 ($90,829), August 15, 2025 ($71,873), and September 15, 2025 ($109,069), by Brian Kneafsey.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	25000	83509.00	255696747	10/15/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/17/2020	Exercise and Hold	BLEND LABS, INC.			25000	02/17/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brian Kneafsey 7250 REDWOOD BLVD., SUITE 300 NOVATO CA 94945	Blend Labs, Inc.	07/15/2025	25000	90829.00
Brian Kneafsey 7250 REDWOOD BLVD., SUITE 300 NOVATO CA 94945	Blend Labs, Inc.	08/15/2025	25000	71873.00
Brian Kneafsey 7250 REDWOOD BLVD., SUITE 300 NOVATO CA 94945	Blend Labs, Inc.	09/15/2025	25000	109069.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the BLND Form 144 filing disclose?

A planned sale of 25,000 Blend Labs common shares with an aggregate market value of $83,509, to be sold around October 15, 2025.

Which broker and exchange are listed for the BLND sale?

The broker is Charles Schwab & Co., Inc., and the shares are listed on the NYSE.

How many Blend Labs shares are outstanding?

The form lists 255,696,747 shares outstanding.

Who is named in recent BLND share sales and what amounts?

Brian Kneafsey sold 25,000 shares on 07/15/2025 for $90,829, 25,000 on 08/15/2025 for $71,873, and 25,000 on 09/15/2025 for $109,069.

When and how were the 25,000 shares to be sold acquired?

Acquired on 02/17/2020 via “Exercise and Hold,” with cash payment.

What is the class of securities in the BLND Form 144?

The filing covers Common stock.